FDA Grants Rybrevant Faspro Accelerated Approval in HNSCC

Company Janssen Biotech (Johnson & Johnson) Event Type FDA accelerated approval Modality EGFR/MET bispecific antibody (subcutaneous) Asset Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Target EGFR; MET Disease Area Recurrent or metastatic head and neck squamous cell carcinoma Summary Source-gap recovery: on November 5, 2026, the US…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *